Verastem Toekomstige groei

Future criteriumcontroles 2/6

De verwachting is dat Verastem de winst en omzet met respectievelijk 41.7% en 37.8% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 49.5% per jaar.

Belangrijke informatie

41.7%

Groei van de winst

49.54%

Groei van de winst per aandeel

Biotechs winstgroei	27.8%
Inkomstengroei	37.8%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Good
Laatst bijgewerkt	10 Aug 2026

Recente toekomstige groei-updates

Analyse-artikel • May 11

Analysts Are Updating Their Verastem, Inc. (NASDAQ:VSTM) Estimates After Its First-Quarter Results

It's been a sad week for Verastem, Inc. ( NASDAQ:VSTM ), who've watched their investment drop 18% to US$4.89 in the...

Recent updates

Narratiefupdate • Aug 10

VSTM: TARGET-D Trials Will Shape Future Upside In Crowded KRAS Space

Verastem's analyst fair value estimate has moved from $20.00 to $18.00 as analysts recalibrate their models and lower price targets in light of recent Q1 and Q2 updates and a more crowded competitive field. Analyst Commentary Recent Street research on Verastem shows a cluster of lower price targets following Q1 and Q2 updates, yet many bullish analysts are maintaining positive views on the stock.

Narratiefupdate • Jun 26

VSTM: Future KRAS Data And Pancreatic Trial Progress Will Drive Repricing

The Verastem analyst price target has been revised lower, with a fair value estimate moving from about $14.00 to about $8.85 as analysts factor in a less favorable long thesis in a more crowded competitive space and updated post-earnings models. Analyst Commentary on Verastem Recent Street research on Verastem reflects a more cautious tone, with several bearish analysts trimming their fair value assumptions and reassessing the long thesis after recent earnings and competitive updates.

Analyse-artikel • May 11

Analysts Are Updating Their Verastem, Inc. (NASDAQ:VSTM) Estimates After Its First-Quarter Results

It's been a sad week for Verastem, Inc. ( NASDAQ:VSTM ), who've watched their investment drop 18% to US$4.89 in the...

Nieuw narratief • Jan 22

RAS And MAPK Cancer Pipeline Will Drive Long Term Upside Potential

Catalysts About Verastem Verastem is an oncology company focused on therapies for RAS and MAPK pathway driven cancers, including KRAS mutated recurrent low grade serous ovarian cancer. What are the underlying business or industry changes driving this perspective?

Analyse-artikel • Dec 26

Verastem, Inc.'s (NASDAQ:VSTM) Share Price Is Still Matching Investor Opinion Despite 26% Slump

Verastem, Inc. ( NASDAQ:VSTM ) shareholders won't be pleased to see that the share price has had a very rough month...

Seeking Alpha • Jul 16

Verastem: The Market Is Ignoring The Progress

Summary FDA approval of AVMAPKI FAKZYNJA CO-PACK marks a transformative milestone, positioning Verastem as a commercial-stage leader in KRAS-mutant LGSOC treatment. Verastem's strong cash position and promising pipeline, including VS-7375 for KRAS G12D, offer significant upside with multiple near-term catalysts ahead. Risks include slow commercial uptake, pipeline uncertainty, and potential future dilution, but current valuation under $5 presents an attractive entry point. I maintain a 3/5 conviction, plan to add to my position below $5.75, and aim to hold long-term as VSTM targets KRAS-driven cancers. Read the full article on Seeking Alpha

Seeking Alpha • May 26

Verastem: Narrowed Market And Less Compelling Efficacy Warrant Rating Downgrade

Summary Verastem's stock plummeted after updates showed reduced efficacy in cancer treatment trials, causing a reassessment of strategy. Updated clinical trial results show a significant drop in response rates, suggesting less robust efficacy than earlier believed. Financially, Verastem has only a year of cash runway and faces significant dilution risks to extend it. Downgrade the recommendation to 'hold' due to increased risks and market volatility associated with microcap stocks. Read the full article on Seeking Alpha

Winst- en omzetgroeiprognoses

NasdaqCM:VSTM - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2028	260	-114	-98	-90	7
12/31/2027	181	-157	-150	-145	8
12/31/2026	116	-166	-166	-162	9
6/30/2026	88	-203	-172	-162	N/A
3/31/2026	50	-194	-161	-151	N/A
12/31/2025	31	-209	-147	-138	N/A
9/30/2025	13	-241	-141	-133	N/A
6/30/2025	2	-167	-120	-120	N/A
3/31/2025	10	-149	-115	-115	N/A
12/31/2024	10	-131	-105	-105	N/A
9/30/2024	10	-93	-109	-109	N/A
6/30/2024	10	-89	-102	-102	N/A
3/31/2024	N/A	-106	-95	-94	N/A
12/31/2023	N/A	-87	-86	-86	N/A
9/30/2023	N/A	-77	-73	-73	N/A
6/30/2023	N/A	-75	-72	-72	N/A
3/31/2023	N/A	-73	-65	-65	N/A
12/31/2022	3	-74	-64	-64	N/A
9/30/2022	3	-73	-57	-57	N/A
6/30/2022	3	-78	-53	-53	N/A
3/31/2022	4	-73	-53	-53	N/A
12/31/2021	2	-71	-54	-54	N/A
9/30/2021	2	-75	-65	-65	N/A
6/30/2021	81	-39	-10	-10	N/A
3/31/2021	84	-45	-19	-19	N/A
12/31/2020	89	-68	-34	-34	N/A
9/30/2020	92	-87	-49	-49	N/A
6/30/2020	22	-130	-122	-122	N/A
3/31/2020	21	-149	N/A	-134	N/A
12/31/2019	17	-149	N/A	-139	N/A
9/30/2019	15	-122	N/A	-120	N/A
6/30/2019	22	-113	N/A	-115	N/A
3/31/2019	28	-89	N/A	-91	N/A
12/31/2018	27	-72	N/A	-75	N/A
9/30/2018	26	-79	N/A	-76	N/A
6/30/2018	10	-81	N/A	-65	N/A
3/31/2018	N/A	-76	N/A	-69	N/A
12/31/2017	N/A	-68	N/A	-57	N/A
9/30/2017	N/A	-61	N/A	-43	N/A
6/30/2017	N/A	-46	N/A	-37	N/A
3/31/2017	N/A	-41	N/A	-29	N/A
12/31/2016	N/A	-36	N/A	-29	N/A
9/30/2016	N/A	-37	N/A	-34	N/A
6/30/2016	N/A	-44	N/A	-39	N/A
3/31/2016	N/A	-51	N/A	-45	N/A
12/31/2015	N/A	-58	N/A	-46	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat VSTM de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat VSTM de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat VSTM de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van VSTM ( 37.8% per jaar) zal naar verwachting sneller groeien dan de markt US ( 12.9% per jaar).

Hoge groei-inkomsten: De omzet van VSTM ( 37.8% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van VSTM naar verwachting over 3 jaar hoog zal zijn

Ontdek groeibedrijven

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/08/23 06:56
Aandelenkoers aan het einde van de dag	2026/08/21 00:00
Inkomsten	2026/06/30
Jaarlijkse inkomsten	2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Verastem, Inc. wordt gevolgd door 29 analisten. 9 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Matthew Cross	Alliance Global Partners
James Molloy	Alliance Global Partners
Matthew Venezia	Alliance Global Partners

Verastem Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus revenue estimates increase by 14%, EPS downgraded

Analysts Are Updating Their Verastem, Inc. (NASDAQ:VSTM) Estimates After Its First-Quarter Results

Forecast to breakeven in 2028

Forecast to breakeven in 2028

Consensus EPS estimates fall by 13%

Consensus revenue estimates increase by 20%

Recent updates

Consensus revenue estimates increase by 14%, EPS downgraded

VSTM: TARGET-D Trials Will Shape Future Upside In Crowded KRAS Space

New major risk - Financial position

New minor risk - Financial position

Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer

Verastem, Inc. to Report Q2, 2026 Results on Aug 06, 2026

New minor risk - Share price stability

New minor risk - Insider selling

Verastem, Inc.(NasdaqCM:VSTM) dropped from Russell 3000 Value Benchmark

VSTM: Future KRAS Data And Pancreatic Trial Progress Will Drive Repricing

Verastem Oncology Demonstrates Clinical Activity of Vs-7375 in Target-D 101 Phase 1/2 Clinical Trial in Patients with Advanced Kras G12d-Mutated Solid Tumors

Verastem Inc Announces Positive Updated Safety and Efficacy Results from Ramp 205 Phase 1B 2A Trial of Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab Paclitaxel in First Line Mpdac

Insufficient new directors

Verastem, Inc. Announces Board Changes

Analysts Are Updating Their Verastem, Inc. (NASDAQ:VSTM) Estimates After Its First-Quarter Results

Verastem, Inc. to Report Q1, 2026 Results on May 07, 2026

Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI FAKZYNJA Combination Therapy

Verastem, Inc., Annual General Meeting, May 21, 2026

New minor risk - Profitability

Forecast to breakeven in 2028

Verastem, Inc. to Report Q4, 2025 Results on Mar 04, 2026

Forecast to breakeven in 2028

RAS And MAPK Cancer Pipeline Will Drive Long Term Upside Potential

President recently sold US$74k worth of stock

Insufficient new directors

Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Verastem, Inc.'s (NASDAQ:VSTM) Share Price Is Still Matching Investor Opinion Despite 26% Slump

Verastem Oncology Announces Management Changes

President notifies of intention to sell stock

Verastem, Inc. has completed a Follow-on Equity Offering in the amount of $89.99962 million.

Consensus EPS estimates fall by 13%

Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2A Dose Escalation Trial of Vs-7375, an Oral Kras G12d (On/Off) Inhibitor, in Patients with Kras G12d Mutant Solid Tumors

Verastem, Inc. to Report Q3, 2025 Results on Nov 04, 2025

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma

Independent Director notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Consensus revenue estimates increase by 20%

Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer

Verastem, Inc. to Report Q2, 2025 Results on Aug 07, 2025

Verastem Oncology Grants Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer

Consensus revenue estimates decrease by 11%

Verastem: The Market Is Ignoring The Progress

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology

Consensus revenue estimates fall by 28%

Verastem Oncology Announces Nature Medicine Publication of the Results from the First-In-Human Phase 1 FRAME Study of Avutometinib in Solid Tumors, Including Low-Grade Serious Ovarian Cancer

President recently sold US$91k worth of stock

New minor risk - Profitability

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/Off) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375) Inhibitor

Price target increased by 18% to US$15.75

Verastem Oncology Announces Positive Updated Results from Ramp 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-Of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma

Verastem, Inc. Announces that FDA Approves AVMAPKI FAKZYNJA for Treating KRAS-mutated Ovarian Cancer

Verastem, Inc. announced that it expects to receive $75.004271 million in funding

Verastem, Inc., Annual General Meeting, May 22, 2025

Verastem, Inc. Auditor Raises 'Going Concern' Doubt

Verastem Oncology Appoints Matthew E. Ros as Chief Operating Officer

Verastem, Inc. announced that it has received $75 million in funding

Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as A Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting

Verastem, Inc. has completed a Follow-on Equity Offering in the amount of $54.995002 million.

Verastem, Inc. has filed a Follow-on Equity Offering.

Verastem Oncology Announces First Patient Dosed with Gfh375/Vs-7375 in A Phase 1/2 Trial in China as Part of Collaboration with Genfleet Therapeutics

Verastem: Narrowed Market And Less Compelling Efficacy Warrant Rating Downgrade

Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer

Verastem Oncology Announces Executive Changes

Verastem, Inc., Annual General Meeting, May 23, 2024

Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Broader Pipeline in RAS Pathway-Driven Cancers